By HANA KAHLEOVA
Nearly each week, a affected person asks me some model of the identical query. If medication like Ozempic work by copying a hormone my intestine already makes, can the correct meals do what the injection does?
Meals and complement entrepreneurs have already answered sure. Frozen dinners now carry GLP-1 Friendly badges. Complement advertisements promise the drug’s results in a capsule. Hundreds of products invoke the hormone, aimed on the roughly 12 percent of U.S. adults who’ve taken certainly one of these drugs. But the time period has no federal definition. The U.S. Division of Agriculture, which has authorized the phrase on some labels, has stressed that its approvals don’t create a typical. In March, Kyle Diamantas, then the Meals and Drug Administration’s prime meals official and now its performing commissioner, told Bloomberg Law the company was conscious of the problem however had no motion deliberate.
The result’s a advertising and marketing declare that borrows the title of a hormone, falls between three regulators and has been examined by none of them. For a well being system nonetheless deciding who ought to get these medication and who ought to pay for them, that’s not a aspect problem. It shapes what sufferers assume they will purchase as an alternative.
What the Science Helps
As a scientific researcher who research weight loss program and sort 2 diabetes, I believe the trustworthy reply is extra attention-grabbing than the label. Meals actually can increase the physique’s personal GLP-1. The hormone is launched by cells lining the gut inside minutes of a meal and, hours later, in response to compounds intestine micro organism make from fiber.
However the proof doesn’t help single-ingredient claims. A scoping review published in July gathered 52 trials of remoted fibers. Most examined a single dose, the standard trial enrolled 19 individuals, and fewer than a 3rd discovered any rise in GLP-1.
The strongest sign my colleagues and I’ve discovered got here from a complete meal. In a randomized crossover trial, 60 males, 20 of them with sort 2 diabetes, ate two breakfasts with the identical energy and proportions of carbohydrate, protein and fats: a tofu burger with inexperienced tea, or a processed pork-and-cheese burger with a sweetened latte. After the plant-based meal, GLP-1 secretion was 30.5 % increased within the males with diabetes, and measures of insulin secretion and beta-cell function improved. The meals additionally differed in fiber, saturated fats and sugar, so we can not say which distinction mattered. What moved the hormone was a sample of consuming, not a molecule.
Even the order of meals on a plate issues. In a small crossover trial in Japan, individuals with sort 2 diabetes who ate fish or meat quarter-hour earlier than rice had increased GLP-1 ranges, slower abdomen emptying and smaller blood sugar swings than once they ate the rice first. None of those results comes from a product, and none of them suits on a sticker.
There may be additionally a restrict that issues for any declare of equivalence. The GLP-1 the intestine makes survives solely a minute or two within the bloodstream. The medication are engineered to resist breakdown and maintain the receptor occupied across the clock, at ranges the physique by no means produces by itself. A meal delivers a pulse. A weekly injection delivers a gentle flood.
A Declare Between Three Regulators
Every company with a stake in these labels has a device that might deal with them. None is getting used.
The USDA’s Meals Security and Inspection Service must approve special statements and claims on meat and poultry labels before they are used. That provides it a gatekeeping function the opposite businesses lack. But FSIS has authorized GLP-1 claims with out saying what they imply, and as of June, 5 corporations had filed 21 extra label requests for meat and poultry merchandise.
The FDA governs most different meals and dietary supplements, however its framework gives little resistance. Typical meals makers might make structure/function claims with out notifying the company. Complement makers want solely notify the FDA inside 30 days of promoting and add a disclaimer that the company has not evaluated the declare. A label saying a product helps GLP-1 can match comfortably in that house, even when it implies one thing nearer to treating weight problems or diabetes. The company has not been idle on GLP-1 advertising and marketing. It has despatched repeated rounds of warning letters to telehealth corporations over deceptive claims about compounded variations of the medication. However that marketing campaign targets drug sellers. The meals and dietary supplements that borrow the hormone’s title haven’t drawn the identical scrutiny.
The Federal Commerce Fee polices promoting. Its 2022 Health Products Compliance Guidance says well being claims require competent and dependable scientific proof, usually randomized, managed human trials, and in some instances a research of the particular product somewhat than an remoted ingredient. Few GLP-1 advertising and marketing claims seem to satisfy that bar. The fee has proven it’ll act on this market: final December it finalized an order in opposition to a telehealth firm over unsubstantiated weight-loss claims and faux critiques tied to the medication. It has declined to say whether or not it’s taking a look at meals and complement claims.
Why It Issues
This isn’t a innocent sticker. A consumer who sees GLP-1 Pleasant on a frozen pizza might assume it does one thing it was by no means examined to do. A affected person who believes a capsule can stand in for a prescription might cease a drug she wants; one weight problems doctor instructed Bloomberg Regulation she had simply seen precisely that. And a affected person on the drug might miss what meals can genuinely supply: a greater hormone response, steadier blood sugar and actual fullness.
What Clinicians and Payers Can Do
The sufferers most uncovered to those claims are sometimes those who can not get the drug. In keeping with the Enterprise Group on Well being, the share of enormous employers protecting GLP-1 medication for weight administration fell from 72 percent in 2025 to 60 percent this year, and 14 % have dropped that protection or plan to in 2027. When protection ends, the demand doesn’t. A few of it’ll land within the complement aisle, the place labels promise the drug’s impact for the worth of a bottle.
Clinicians can shut a part of that hole within the examination room. We already ask sufferers which dietary supplements they take. We must always ask particularly about merchandise bought as GLP-1 boosters or drug alternate options, particularly when a affected person has stopped a GLP-1 or misplaced protection for one. As I argued here recently, brief visits make the prescription the default. In addition they depart little time to ask what a affected person purchased on the best way house. That query opens the dialog about what meals can actually do.
Payers could make the trustworthy model simpler to succeed in. A plan that drops a drug and gives nothing as an alternative leaves sufferers to the entrepreneurs. Medicare covers medical nutrition therapy just for individuals with diabetes or kidney illness, or a kidney transplant up to now 36 months. Many employers that also cowl the medication already require sufferers to affix a weight administration program. These packages, and plans which have dropped protection, ought to pay for counseling with a registered dietitian, so sufferers study what a meal can do for their very own hormone response whether or not or not they keep on the drug.
Three Fixes
First, FSIS ought to cease approving GLP-1 claims till it defines them, and any definition ought to require human proof: examined on the product, measuring the hormone itself, on the quantity individuals really eat.
Second, the FDA ought to problem steering stating that claims evaluating a meals or complement to GLP-1 medication, or promising drug-like results on weight or blood sugar, are implied illness claims somewhat than construction/operate claims. That may transfer probably the most deceptive claims out of the flippantly policed class they now occupy.
Third, the FTC ought to apply its present substantiation normal to GLP-1 advertising and marketing, beginning with warning letters to probably the most aggressive complement claims. It doesn’t want new authority to take action.
Higher nonetheless, the three businesses ought to coordinate, so {that a} declare can not escape scrutiny by transferring from a meat label to a complement bottle to an internet advert.
A long time of analysis have taught us that GLP-1 is a sign with a timescale, a location and a dose. A sticker flattens all three. Meals can do greater than most individuals assume, and fewer than the labels promise. Sufferers, and the clinicians and well being plans who look after them, deserve the trustworthy model of each.
Hana Kahleova, MD, PhD, is a doctor board-certified in inner drugs, endocrinology and life-style drugs, and director of scientific analysis on the Physicians Committee for Responsible Medicine, a nonprofit that promotes plant-based vitamin and preventive drugs. She led the plant-based meal research described right here and stories no monetary relationships with meals, complement or pharmaceutical corporations.
